 LA JOLLA, Calif., April 22, 2021 GLOBE NEWSWIRE -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that it has received two milestone payments under MediciNovas assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payments, which total 4 million, are a result of the successful achievement of two clinical development milestones for a gene therapy product based on AAV adeno-associated virus vector technology that is covered under the assignment agreement. 